The Food and Drug Administration has granted Fast Track designation to AMX0114 for the treatment of amyotrophic lateral sclerosis (ALS).

UC Riverside study may lead to new treatments for multiple sclerosis. Multiple sclerosis (MS) affects an estimated 2.3 ...

SineuGene Therapeutics, a clinical-stage biotechnology company focused on gene therapies for neurological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug ...

In multiple sclerosis (MS), an alteration of neuronal metabolism caused by dysfunction of its proteasome, the cellular machinery responsible for recycling proteins, contributes to neurodegeneration in ...

Aim To quantify structural and functional degeneration in the retinal nerve fibre layer (RNFL) of patients with multiple sclerosis (MS) over a 2-year time period, and to analyse the effect of prior ...

In 2024, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress celebrated a remarkable 40 years of pioneering work. Regional committees have emerged around the ...

Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have inflammation in the cerebellum, the part of the brain that helps control movement ...

Synapse loss is well-documented in many neurodegenerative diseases, with recently strong associations observed in amyotrophic lateral sclerosis (ALS). Emerging evidence demonstrates thattransactive ...

People with multiple sclerosis, an autoimmune disease that affects the central nervous system (CNS), are known to have imbalances in their gut microbiome — the collection of bacteria, fungi, and ...

Source Reference: Ostkamp P, Schwab N "Effects of latitude and sunlight on multiple sclerosis severity: two peas in a pod?" Neurology 2022; DOI: 10.1212/WNL.0000000000200105.